Infantile-onset Pompe disease (CRIM-negative): what to do when Alglucosidase alfa dose escalation has not improved walking or gross motor outcomes
This protocol addresses the clinical decision point in CRIM-negative infantile-onset Pompe disease — presenting from the first months of life — where high-dose Alglucosidase alfa has failed to deliver the expected motor gains and a further escalation is warranted.
Clinical scenario
Infantile-onset Pompe disease with disease onset in the first months of life in a patient who is confirmed or presumed to be CRIM (Cross Reactive Immune Material) negative. Approximately one third of infantile Pompe disease patients, depending on genotype, express no GAA protein and are defined CRIM-negative. These patients carry a higher risk of developing antibodies against recombinant enzymes during enzyme replacement therapy. Infants with unknown CRIM status are appropriately managed as if CRIM-negative.
Prior treatment and failure condition
This protocol applies after escalation of Alglucosidase alfa to high-dose regimens — used in classic infantile disease with suboptimal response, plateau, or clinical decline — has not achieved the intended goals: improved walking ability and improved gross motor outcomes. Persistent motor insufficiency at this point indicates the need for a different therapeutic strategy.
Next-step treatment approach
The protocol involves switching to a second-generation enzyme replacement therapy. The full structured algorithm — including dosing, dose-escalation criteria, and clinical decision thresholds — is available in the complete regimen.
Treatment goal: stabilization or improvement of skeletal muscle and respiratory function.
References
DOI: 10.1186/s13023-024-03373-w
- About one third of infantile Pompe disease patients, depending on their genotype, do not express any GAA protein and are defined CRIM negative.
- CRIM negative patients have a higher risk of producing antibodies against recombinant enzymes when treated with enzyme replacement therapy (ERT).
- Therefore, it may be advisable that infantile-onset patients with unknown CRIM status are treated as if they were CRIM negative.
- Switching to a second-generation ERT can be considered if there is no indication of skeletal muscle and/or respiratory function stabilization or improvements after at least a year on first-generation recombinant alpha-glucosidase, or if the patient suffers from severe infusion-associated reactions that cannot be adequately managed.
View source ↗